ARRB1 was positively correlated with TMB and MSI in ESCA but was negatively correlated with these two parameters in BRCA, THCA, STAD, READ, PRAD, and LUSC, implying that in patients with these cancers with high ARRB1 expression, immune cell targeting neoantigens are less frequent and the efficacy of immune checkpoint inhibitors may be diminished as a result. This evidence concerns the gene ARRB1 and cancer.